Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) will likely be issuing its Q3 2026 results on Monday, November 16th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.18) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last announced its earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). On average, analysts expect Brainstorm Cell Therapeutics to post ($3.01) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year.
Brainstorm Cell Therapeutics Stock Performance
NASDAQ:BCLI traded down $0.01 during mid-day trading on Friday, hitting $0.99. 47,716 shares of the company’s stock traded hands, compared to its average volume of 19,730. The company has a fifty day moving average of $0.92 and a 200 day moving average of $0.85. Brainstorm Cell Therapeutics has a twelve month low of $0.46 and a twelve month high of $1.69. The company has a market capitalization of $14.66 million, a P/E ratio of -0.29 and a beta of 0.35.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for neurodegenerative diseases. The company’s technology platform uses autologous mesenchymal stem cells, derived from a patient’s bone marrow and induced to produce neurotrophic factors that may support nerve-cell survival and repair. Its lead product candidate, NurOwn, also known as debamestrocel or MSC-NTF cells, is being developed primarily for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis.
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
